DCC-3116 is an orally active ULK1/2 inhibitor. DCC-3116 can promote autophagy in lung cancer cells by inhibiting KRASG12C signaling, thereby inhibiting the proliferation of lung cancer cells and exerting anti-cancer effects.
DCC-3116 (100 nM, 72 h) alone inhibits the proliferation of NCI-H2122 and Calu-1 cells, decreases the expression of pS318-ATG13, and has a synergistic effect when combined with Sotorasib [1].
DCC-3116 (3 or 30 mg/kg/day for 56 days, p.o. and p.i.) alone or in combination with Sotorasib can inhibit tumor growth in mouse models of NSCLC lung cancer[1].
References:
[1]. Ghazi PC, et al. Inhibition of ULK1/2 and KRAS G12C controls tumor growth in preclinical models of lung cancer. bioRxiv [Preprint]. 2024 Feb 8:2024.02.06.579200.